JP2019510826A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510826A5
JP2019510826A5 JP2019502544A JP2019502544A JP2019510826A5 JP 2019510826 A5 JP2019510826 A5 JP 2019510826A5 JP 2019502544 A JP2019502544 A JP 2019502544A JP 2019502544 A JP2019502544 A JP 2019502544A JP 2019510826 A5 JP2019510826 A5 JP 2019510826A5
Authority
JP
Japan
Prior art keywords
trapidil
composition
compound
levodopa
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019502544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510826A (ja
JP7049683B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/025788 external-priority patent/WO2017176652A2/en
Publication of JP2019510826A publication Critical patent/JP2019510826A/ja
Publication of JP2019510826A5 publication Critical patent/JP2019510826A5/ja
Priority to JP2022044284A priority Critical patent/JP7794668B2/ja
Application granted granted Critical
Publication of JP7049683B2 publication Critical patent/JP7049683B2/ja
Priority to JP2024041690A priority patent/JP2024095682A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019502544A 2016-04-04 2017-04-03 トラピジルを使用する錐体外路症候群の処置 Active JP7049683B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022044284A JP7794668B2 (ja) 2016-04-04 2022-03-18 トラピジルを使用する錐体外路症候群の処置
JP2024041690A JP2024095682A (ja) 2016-04-04 2024-03-15 トラピジルを使用する錐体外路症候群の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317983P 2016-04-04 2016-04-04
US62/317,983 2016-04-04
PCT/US2017/025788 WO2017176652A2 (en) 2016-04-04 2017-04-03 Treating extrapyramidal syndrome using trapidil

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022044284A Division JP7794668B2 (ja) 2016-04-04 2022-03-18 トラピジルを使用する錐体外路症候群の処置

Publications (3)

Publication Number Publication Date
JP2019510826A JP2019510826A (ja) 2019-04-18
JP2019510826A5 true JP2019510826A5 (enExample) 2020-05-14
JP7049683B2 JP7049683B2 (ja) 2022-04-07

Family

ID=60001402

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019502544A Active JP7049683B2 (ja) 2016-04-04 2017-04-03 トラピジルを使用する錐体外路症候群の処置
JP2022044284A Active JP7794668B2 (ja) 2016-04-04 2022-03-18 トラピジルを使用する錐体外路症候群の処置
JP2024041690A Pending JP2024095682A (ja) 2016-04-04 2024-03-15 トラピジルを使用する錐体外路症候群の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022044284A Active JP7794668B2 (ja) 2016-04-04 2022-03-18 トラピジルを使用する錐体外路症候群の処置
JP2024041690A Pending JP2024095682A (ja) 2016-04-04 2024-03-15 トラピジルを使用する錐体外路症候群の処置

Country Status (10)

Country Link
US (4) US10350212B2 (enExample)
EP (1) EP3442538B1 (enExample)
JP (3) JP7049683B2 (enExample)
CN (2) CN109310700A (enExample)
AU (1) AU2017246334C1 (enExample)
CA (1) CA3054674A1 (enExample)
DK (1) DK3442538T3 (enExample)
ES (1) ES3039958T3 (enExample)
FI (1) FI3442538T3 (enExample)
WO (1) WO2017176652A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3054674A1 (en) 2016-04-04 2017-12-10 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
JP2021532098A (ja) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達
EP4069239A4 (en) * 2019-12-02 2023-11-29 Sinopia Biosciences, Inc. Treating cognitive disorders using trapidil
IL296788A (en) * 2020-03-26 2022-11-01 Sinopia Biosciences Inc Isotopically labeled trepidil histories
WO2024053728A1 (ja) * 2022-09-09 2024-03-14 住友ファーマ株式会社 対象の状態の予測およびその応用
CN116754348B (zh) * 2023-06-06 2024-03-08 华北理工大学 基于zif-8-90材料的泡腾片、其制备方法及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4739044A (en) 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IT1222414B (it) 1987-07-31 1990-09-05 Chiesi Farma Spa Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
JPH02268185A (ja) * 1989-04-04 1990-11-01 Biogal Gyogyszergyar 5―メチル―7―(ジエチルアミノ)―S―トリアゾロ(1,5―a)ピリミジン及びその酸付加塩の製造方法
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
JP3195391B2 (ja) 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5348853A (en) 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5567583A (en) 1991-12-16 1996-10-22 Biotronics Corporation Methods for reducing non-specific priming in DNA detection
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DE19514048A1 (de) * 1995-04-13 1996-10-17 Rentschler Arzneimittel Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5869717A (en) 1997-09-17 1999-02-09 Uop Llc Process for inhibiting the polymerization of vinyl aromatics
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Cd40シグナル遮断剤
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20060166972A1 (en) 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
US20080242657A1 (en) 2004-03-26 2008-10-02 Marino Michael J Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
WO2007061798A2 (en) * 2005-11-18 2007-05-31 Cornell Research Foundation, Inc. Nicotinoyl riboside compositions and methods of use
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
CA2721797C (en) 2008-04-18 2018-02-27 Gary Zabow Magnetic microstructures for magnetic resonance imaging
EP3225697A3 (en) 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
US20140045856A1 (en) * 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
KR101534395B1 (ko) 2013-08-01 2015-07-09 서울대학교산학협력단 트라피딜을 유효성분으로 포함하는 골 관련 질환의 예방 또는 치료용 조성물
WO2017059118A1 (en) * 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
WO2017117240A1 (en) 2015-12-29 2017-07-06 JONES AND MALTERER TECHNOLOGY INNOVATIONS INCORPORATED, d/b/a JAMTek Multi-point synchronizable and scalable lighting control systems
CA3054674A1 (en) * 2016-04-04 2017-12-10 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
IL296788A (en) 2020-03-26 2022-11-01 Sinopia Biosciences Inc Isotopically labeled trepidil histories

Similar Documents

Publication Publication Date Title
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
JP2022058688A5 (enExample)
JP2017529332A5 (enExample)
HRP20170531T1 (hr) Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze
FI3287124T3 (fi) Ketamiinin oraalinen annosmuoto
JP2010529118A5 (enExample)
JP2013525444A5 (enExample)
JP2019524822A5 (enExample)
JP2016518337A5 (enExample)
CO2019014047A2 (es) Imidazopirimidinas diazabicíclicas sustituidas y su uso para el tratamiento de trastornos respiratorios
JP2013526544A5 (enExample)
JP2012193216A5 (enExample)
EP4509183A3 (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
JP2016147915A5 (enExample)
JP2016106150A5 (enExample)
FI3442538T3 (fi) Levodopan aiheuttaman dyskinesian hoito trapidiililla
JP2015523407A5 (enExample)
JP2016185995A5 (enExample)
JP2015529225A5 (enExample)
JP2013520405A5 (enExample)
JP2018520189A5 (enExample)
JP2017506624A5 (enExample)
JP2012524089A5 (enExample)
JP2018537535A5 (enExample)
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations